A  team of researchers from Cleveland Clinic share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the US.   The report comes ...

Cancer therapeutic resistance occurs as cancers develop resistance to treatments such as chemotherapy, radiotherapy and targeted therapies, through many different mechanisms. These include ...

in a Chinese PD-L1-positive non-small cell lung cancer (NSCLC) population. That led some market observers to predict the drug could become a 'Keytruda killer' and potentially a replacement for ...

IMD Technologies has recently introduced the IMDT V2N SoM based on the newly launched Renesas RZ/V2N low-power AI MPU and its ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

After hours: March 18 at 7:11:52 PM EDT Loading Chart for PD ...

1. Current NAV: The Current Net Asset Value of the Axis Bluechip Fund as of Mar 18, 2025 is Rs 55.70 for Growth option of its Regular plan. 2. Returns: Its trailing returns over different time periods ...